Focused on the neural and vascular axes, combining an AI platform with nanomedicine to develop effective, safe, and precise next-generation therapies.
Future AI's core value lies not only in finding an effective drug, but in systematically identifying and removing high-risk candidates early in R&D. By embedding toxicology and safety assessment into AI-driven selection and decision-making, toxicology becomes a key determinant of candidate survival rather than a late-stage check.
01
AiPLEX selection engine
Combines pharmacology, dosage-form assessment, and patent/clinical needs to precisely match drugs to indications across multiple disease areas.
Pharmacology · Dosage form · Patent/Clinical
02
AiTOX toxicology
Provides safety and ADMET assessment, aiming for animal-test-free toxicology prediction that screens out high-risk candidates early.
ADMET · DDI · Safety
03
Platforms in concert
AiPLEX and AiTOX work together to systematically screen and rank drug candidates, completing process development and in vitro / in vivo validation.
Candidates · Systematic · Ranking
04
Current focus
Has identified drug candidates that improve blood-brain-barrier penetration and promote neural repair, while advancing patent filing and toxicology-led preclinical validation.
BBB · Neural repair · Dementia
AI selection engine
Finding the candidates worth pursuing, for every indication.
The pipeline spans ten indications including erectile dysfunction, vascular dementia, pulmonary arterial hypertension, and Alzheimer's disease; lead product FPT-001 has obtained Phase II clinical approval in Australia.
Erectile dysfunction
PBF Pharma
Erectile dysfunction (ED)
Benign prostatic hyperplasia
MOU in progress
Benign prostatic hyperplasia (BPH)
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH)
Coronary artery disease
Coronary artery disease (CAD)
Metabolic-associated steatohepatitis
MOU in progress
Metabolic-associated steatohepatitis (MASH)
Androgenetic Alopecia
Androgenetic Alopecia (AGA)
Vascular Dementia
MOU in progress
Vascular Dementia
Traumatic brain injury
Traumatic brain injury (TBI)
Alzheimer's disease
Alzheimer's disease (AD)
Myopia
In talks
Myopia
About the company
Founded in 2021, Future PharmaTech focuses on the body's two great axes of life — neural and vascular — using an innovative AI drug-development platform and nanomedicine to accelerate discovery, complete trials faster, and create effective, safe, and precise therapies for hard-to-treat diseases such as vascular dementia (VaD) and erectile dysfunction (ED).
Guided by the principle of "not changing the patient's lifestyle," the company designs next-generation therapies that balance efficacy and comfort. Its core technology, the Future-AI platform, integrates drug repurposing and mechanism simulation to achieve precise delivery across the blood-brain barrier (BBB), raising efficacy while reducing side effects.
The team brings together senior experts in pharmaceutical R&D, AI, and business operations, and partners actively with leading research institutions and pharmaceutical companies — aiming to shorten the development cycle to within five years and deliver breakthrough therapies.
2
AI Platforms
10
Drug Candidates
10
Patent Regions
Media
A strategic MOU combining an AI drug-discovery platform with international manufacturing, regulatory, and market-access resources to drive new drugs from clinical development to global commercialization.
Media
FPT-001 has cleared the Australian CTN and obtained Phase II approval — a key milestone; FPT-003 is also advancing international licensing in parallel.
Media
Lead product FPT-001 has submitted its Phase II CTN application to an Australian HREC, formally launching the company's international clinical program.
